Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease

Background Development of disease‐modifying treatments for Huntington's disease (HD) could be aided by the use of imaging biomarkers of disease progression. Positron emission tomography (PET) with 11C‐UCB‐J, a radioligand for the brain‐wide presynaptic marker synaptic vesicle protein 2A (SV2A),...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 38; no. 8; pp. 1515 - 1526
Main Authors Delva, Aline, Van Laere, Koen, Vandenberghe, Wim
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.08.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Development of disease‐modifying treatments for Huntington's disease (HD) could be aided by the use of imaging biomarkers of disease progression. Positron emission tomography (PET) with 11C‐UCB‐J, a radioligand for the brain‐wide presynaptic marker synaptic vesicle protein 2A (SV2A), detects more widespread brain changes in early HD than volumetric magnetic resonance imaging (MRI) and 18F‐fludeoxyglucose (18F‐FDG) PET, but longitudinal 11C‐UCB‐J PET data have not been reported. The aim of this study was to compare the sensitivity of 11C‐UCB‐J PET, 18F‐FDG PET, and volumetric MRI for detection of longitudinal changes in early HD. Methods Seventeen HD mutation carriers (six premanifest and 11 early manifest) and 13 healthy controls underwent 11C‐UCB‐J PET, 18F‐FDG PET, and volumetric MRI at baseline (BL) and after 21.4 ± 2.7 months (Y2). Within‐group and between‐group longitudinal clinical and imaging changes were assessed. Results The HD group showed significant 2‐year worsening of Unified Huntington's Disease Rating Scale motor scores. There was significant longitudinal volume loss within the HD group in caudate (−4.5% ± 3.8%), putamen (−3.6% ± 3.5%), pallidum (−3.0% ± 2.7%), and frontal cortex (−2.0% ± 2.1%) (all P < 0.001). Within the HD group there was longitudinal loss of putaminal SV2A binding (6.4% ± 8.8%, P = 0.01) and putaminal glucose metabolism (−2.8% ± 4.4%, P = 0.008), but these changes were not significant after correction for multiple comparisons. Premanifest subjects at BL only had significantly lower SV2A binding than controls in basal ganglia structures, but at Y2 additionally had significant SV2A loss in frontal and parietal cortex, indicating spread of SV2A loss from subcortical to cortical regions. Conclusions Volumetric MRI may be more sensitive than 11C‐UCB‐J PET and 18F‐FDG PET for detection of 2‐year brain changes in early HD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Bibliography:The study was supported by UZ Leuven (Fund for Academic Studies and Klinische Onderzoeks‐en Opleidingsraad) and KU Leuven (C24/17/063).
A.D. is a PhD fellow of the Fund for Scientific Research Flanders (FWO). K.V.L. is a Senior Clinical Investigators of the FWO. There are no other financial disclosures or conflicts of interest.
Relevant conflicts of interest/financial disclosures
Funding agencies
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0885-3185
1531-8257
1531-8257
DOI:10.1002/mds.29501